Gynaecomastia in Sugar Land is a concern for many men seeking answers about enlarged male breast tissue. Gynaecomastia is a benign but often distressing condition involving the growth of glandular breast tissue in males, affecting men at any age — from newborns to older adults. Whether caused by hormonal shifts, medications, or an underlying health condition, it deserves thorough clinical evaluation rather than dismissal as a cosmetic issue. This article explains what gynaecomastia is, its common causes, how it is diagnosed, the treatment options available, and how to find appropriate specialist care.

What Is Gynaecomastia and Who Does It Affect?

Gynaecomastia is a benign enlargement of glandular breast tissue in males, most common during puberty, the neonatal period, and older adulthood, and can cause significant psychological distress despite not being inherently dangerous.

Gynaecomastia is a benign medical condition characterised by the enlargement of glandular breast tissue in males. Unlike pseudogynaecomastia — which refers to an increase in fatty tissue without glandular involvement — true gynaecomastia involves the proliferation of ductal and stromal tissue within the male breast. The condition can affect one or both breasts and may present with tenderness, firmness, or a palpable disc of tissue beneath the nipple.

Gynaecomastia is far more common than many people realise. It can occur at virtually any age, but it is particularly prevalent during three distinct life stages:

• Neonatal period — due to the transfer of maternal oestrogens

• Puberty — affecting a substantial proportion of adolescent males (estimates vary but are commonly cited in the range of 50–70%), typically resolving within one to two years without treatment

• Older adulthood — particularly in men aged 50 and above, as the relative balance between oestrogen and androgen activity shifts with age

The hormonal changes of older adulthood reflect a relative increase in oestrogenic effect rather than simply a fall in total testosterone; changes in sex hormone-binding globulin and body composition also play a role. Further information on prevalence and natural history is available from NICE CKS (Gynaecomastia) and the NHS (Gynaecomastia — enlarged male breasts).

Whilst the condition is not inherently dangerous, it can cause significant psychological distress, including reduced self-confidence, social withdrawal, and anxiety. It is important to approach gynaecomastia with clinical sensitivity, recognising both its physical and emotional dimensions. Men of all backgrounds and body types can be affected, and the condition should never be dismissed as merely cosmetic without appropriate clinical evaluation.

Common Causes of Enlarged Male Breast Tissue

Gynaecomastia is caused by an imbalance between oestrogen and androgen activity; causes include physiological hormonal shifts, a wide range of medications, and pathological conditions such as testicular tumours or hypogonadism.

The underlying cause of gynaecomastia is typically an imbalance between oestrogen and androgen activity within breast tissue. Even though males produce oestrogen in small quantities, any relative increase in oestrogenic effect — or decrease in androgenic effect — can stimulate glandular growth. Identifying the root cause is essential for guiding appropriate management.

Physiological causes account for the majority of cases and include the hormonal fluctuations of puberty and the age-related shift in oestrogen–androgen balance seen in older men. These forms often resolve without intervention.

Pharmacological causes are also significant. A wide range of prescribed and over-the-counter medicines have been associated with gynaecomastia, including:

• Anabolic steroids and androgens — paradoxically, these can convert to oestrogen via aromatisation

• Anti-androgens — such as spironolactone, finasteride, and certain prostate cancer treatments (e.g., bicalutamide)

• Antipsychotics — particularly those that elevate prolactin, such as risperidone and haloperidol; evidence for antidepressants (including SSRIs) is less consistent and varies by agent

• Cardiovascular drugs — including digoxin; evidence for calcium channel blockers varies and is not established for all agents in this class

• H2-receptor antagonists — such as cimetidine

• Antifungals — such as ketoconazole

• Some antiretroviral agents — particularly certain protease inhibitors

• Recreational substances — cannabis, alcohol, and opioids have all been associated with gynaecomastia

This list is not exhaustive; the BNF and individual Summary of Product Characteristics (SmPC) documents should be consulted for specific agents. Patients should not stop or alter any prescribed medicine without first seeking medical advice, as the risks of stopping treatment may outweigh the benefit of addressing gynaecomastia.

Pathological causes must also be considered and may include hypogonadism (including Klinefelter syndrome, which also carries an elevated risk of male breast cancer), hyperprolactinaemia due to pituitary disease, hyperthyroidism, chronic liver disease, renal failure, and — importantly — testicular or adrenal tumours that secrete oestrogen or human chorionic gonadotrophin (hCG). Malnutrition and refeeding syndrome can also trigger the condition. Because some underlying causes require urgent investigation, a thorough clinical assessment is always warranted when gynaecomastia presents in an adult male.

Diagnosis and When to Seek Medical Advice

Diagnosis involves clinical history, physical examination, and targeted investigations including blood tests and testicular ultrasound; urgent referral is warranted if red-flag features such as a hard lump, nipple discharge, or skin changes are present.

Diagnosing gynaecomastia begins with a detailed clinical history and physical examination. A clinician will typically assess the onset and duration of breast enlargement, any associated symptoms such as pain or nipple discharge, current medications, recreational drug use, and relevant medical history. On examination, true gynaecomastia presents as a firm, rubbery, concentric disc of tissue beneath the areola, distinguishable from the softer, diffuse fatty tissue of pseudogynaecomastia. Testicular examination should also be performed to identify any masses.

Investigations are guided by clinical suspicion and may include:

• Blood tests — including serum testosterone, luteinising hormone (LH), follicle-stimulating hormone (FSH), oestradiol, prolactin, thyroid function, liver function, and renal function

• hCG levels — to screen for germ cell tumours

• Testicular ultrasound — if a testicular mass is suspected on examination

• Karyotype — if clinical features suggest Klinefelter syndrome

• Breast imaging — when malignancy is suspected, referral to a breast clinic for triple assessment (clinical examination, imaging, and biopsy if indicated) is the appropriate pathway; imaging is not routinely required for classic benign presentations

When to seek urgent medical advice

Unilateral breast enlargement can occur in benign gynaecomastia and does not in itself constitute an emergency. However, the following features should prompt prompt medical review and may warrant urgent referral under the NICE NG12 suspected cancer pathway (2-week wait):

• A hard, irregular, or fixed breast lump

• Nipple discharge, particularly if bloodstained

• Skin or nipple changes (e.g., puckering, inversion, ulceration)

• Axillary lymphadenopathy

• Associated unexplained weight loss, fatigue, or systemic symptoms

• Breast changes in the absence of an obvious physiological explanation

Male breast cancer is rare, accounting for approximately 1% of all breast cancers, but early assessment ensures that serious underlying conditions are not overlooked. If your GP considers any of these features to be present, they may refer you to a breast clinic urgently. Further information on red-flag symptoms is available from the NHS (Breast cancer in men).

Treatment Options Available for Gynaecomastia

Treatment depends on cause and severity, ranging from watchful waiting and addressing underlying conditions to off-label medical therapy with SERMs or, for established cases, surgical intervention such as subcutaneous mastectomy.

The management of gynaecomastia depends on its underlying cause, duration, severity, and the degree of distress it causes the individual. In many cases — particularly in adolescents with pubertal gynaecomastia — watchful waiting is the most appropriate initial approach, as the condition frequently resolves spontaneously within one to two years.

Addressing the underlying cause is the first priority. Where a causative medicine has been identified, a specialist may consider switching to an alternative agent; this should only be done under medical supervision and after weighing the risks of altering treatment. Treating an underlying endocrine disorder — such as hypogonadism, hyperthyroidism, or hyperprolactinaemia — or a systemic illness can result in improvement. In men with confirmed hypogonadism, testosterone replacement therapy, initiated and monitored by a specialist, may be appropriate.

Medical therapy may be considered in cases of recent-onset, painful, or persistent gynaecomastia, typically under specialist guidance. Options include:

• Selective oestrogen receptor modulators (SERMs) such as tamoxifen or raloxifene, which have demonstrated efficacy in reducing breast volume and tenderness in clinical studies. It is important to note that these medicines are not licensed for this indication in the UK and their use is therefore off-label. They would only be initiated by an endocrinologist or other relevant specialist following a thorough discussion of potential benefits and risks. Risks include venous thromboembolism (VTE) and other class-specific adverse effects; patients should consult the BNF and the relevant SmPC, and report any suspected side effects via the MHRA Yellow Card scheme.

• Aromatase inhibitors such as anastrozole have been studied but evidence for their use in gynaecomastia remains limited; they are not routinely recommended, particularly in pubertal gynaecomastia, and would only be considered in specialist settings.

Surgical intervention is the most definitive treatment for established or longstanding gynaecomastia, particularly where fibrotic tissue has developed and is unlikely to respond to medical therapy. Surgical options include subcutaneous mastectomy and liposuction-assisted techniques. Surgery is generally considered when the condition has persisted for more than twelve months, causes significant psychological distress, or has not responded to conservative measures.

Access to surgical treatment on the NHS varies according to local commissioning policies; some clinical commissioning groups or integrated care boards may not routinely fund surgery for gynaecomastia unless specific clinical criteria are met. Patients should discuss NHS eligibility with their GP or specialist. Where surgery is planned, patients should be counselled thoroughly regarding realistic outcomes, potential risks (including scarring and recurrence), and the importance of weight stability and cessation of any causative substances prior to the procedure.

Finding Specialist Care and Support

Assessment should begin with a GP, who can refer to an endocrinologist, urologist, or breast surgeon as appropriate; clinicians should be verified on the GMC Specialist Register and services checked via the CQC.

For individuals seeking assessment and treatment for gynaecomastia, the first point of contact should be their GP, who can conduct an initial evaluation, arrange relevant investigations, and refer to an appropriate specialist. Depending on the suspected cause, referral may be made to an endocrinologist, urologist, or breast surgeon. Where features raise concern about malignancy, an urgent referral to a breast clinic under the NICE NG12 2-week-wait pathway may be appropriate.

Relevant specialists may include:

• Endocrinologists — for hormonal evaluation, medical management, and conditions such as hypogonadism or hyperprolactinaemia

• Urologists — particularly where testicular pathology is suspected

• Breast surgeons or plastic surgeons — for surgical consultation and intervention in established cases

When choosing a provider, patients are encouraged to:

• Verify that the clinician is registered on the GMC Specialist Register for their relevant specialty (searchable via the GMC online register)

• Check service quality and inspection reports via the Care Quality Commission (CQC)

• Request a thorough pre-operative consultation that includes discussion of risks, recovery, and expected outcomes

• Ensure that psychological support is available, given the emotional impact the condition can carry

Support groups and online communities can also provide valuable peer support for men navigating this condition. Open communication with your healthcare team — including your GP, specialist, and any allied health professionals involved in your care — remains the cornerstone of effective management. If you experience any suspected side effects from medicines prescribed for gynaecomastia, these should be reported via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk).

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions